US equities |
NVDA $233.95 ▲+1.34% MU $1,074.89 ▼-2.05% TSLA $370.59 ▲+4.65% SPCX $158.96 ▲+7.35% SNDK $1,719.99 ▼-3.79% AMD $633.91 ▲+2.95% STX $848.99 ▼-10.21% INTC $119.33 ▼-0.56%
FinancialContent

ClearPoint Neuro Inc. - Common Stock (NQ:CLPT)

10.89 -0.55 (-4.85%)
Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about ClearPoint Neuro Inc. - Common Stock

< Previous 1 2 3 4 5 Next >
These stocks that are showing activity before the opening bell on Tuesday. ↗
Via Chartmill
News headline image
ClearPoint Neuro (CLPT) Q2 2026 Earnings Call Transcript ↗
Revenue grew 18% to $10.9 million as neurosurgery navigation surged 62%. 
Via The Motley Fool
Topics Earnings
News headline image
ClearPoint Neuro Q2 Earnings Call Highlights ↗
ClearPoint Neuro (NASDAQ:CLPT) reported second-quarter 2026 revenue growth while outlining a shift in investment priorities toward clinical capacity, preclinical laboratory services and technologies... 
Via MarketBeat
Topics Earnings
ClearPoint Neuro Inc (NASDAQ:CLPT) Reports Q4 2025 Revenue Beat Amid Widened Loss, Shares Fall ↗
Via Chartmill
Stay updated with the stocks that are on the move in today's after-hours session. ↗
Via Chartmill
News headline image
ClearPoint Neuro Reports Second Quarter 2026 Results
From ClearPoint Neuro, Inc.
Via ACCESS Newswire
News headline image
ClearPoint Neuro Congratulates Partner Aspen Neuroscience on FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel
From ClearPoint Neuro, Inc.
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce Second Quarter 2026 Results August 3, 2026
From ClearPoint Neuro, Inc.
Via ACCESS Newswire
These stocks are moving in today's session ↗
Via Chartmill
Gapping stocks in Wednesday's session ↗
Via Chartmill
Discover the top movers in Wednesday's pre-market session. ↗
Via Chartmill
News headline image
ClearPoint Neuro Enters into 10-year Focused Ultrasound Development Partnership with Sungkyunkwan University, South Korea, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Via ACCESS Newswire
News headline image
ClearPoint Neuro Q1 Earnings Call Highlights ↗
ClearPoint Neuro (NASDAQ:CLPT) reported record first-quarter 2026 revenue and reaffirmed its full-year outlook, as management highlighted growth in its legacy neurosurgical device business and early... 
Via MarketBeat
Topics Earnings
News headline image
ClearPoint (CLPT) Q1 2026 Earnings Transcript ↗
ClearPoint (CLPT) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
ClearPoint Neuro Reports First Quarter 2026 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces CE Marking of Velocity Alpha MR High Speed Surgical Drill System, Further Expanding Drug Delivery Ecosystem and Global Footprint
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce First Quarter 2026 Results May 13, 2026
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces FDA Clearance of the Velocity Alpha(R) MR High Speed Surgical Drill System and First Clinical Use, Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Canadian Approval for its Navigation System Further Expanding Our Drug Delivery Ecosystem and Global Footprint
Via ACCESS Newswire
News headline image
ClearPoint Neuro (CLPT) Earnings Call Transcript ↗
ClearPoint Neuro (CLPT) Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
ClearPoint Neuro Reports Fourth Quarter and Full Year 2025 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Announce Fourth Quarter and Full Year 2025 Results March 17, 2026
Via ACCESS Newswire
Let's uncover which stocks are experiencing notable gaps during today's session. ↗
Via Chartmill
Get insights into the top gainers and losers of Monday's pre-market session. ↗
Via Chartmill
News headline image
ClearPoint Neuro Announces Preliminary Unaudited Fourth Quarter and Full Year 2025 Revenue
Via ACCESS Newswire
News headline image
ClearPoint Neuro Completes Acquisition of IRRAS
Via ACCESS Newswire
News headline image
ClearPoint Neuro Reports Third Quarter 2025 Results
Via ACCESS Newswire
News headline image
ClearPoint Neuro Announces Agreement to Acquire IRRAS
Via ACCESS Newswire
News headline image
ClearPoint Neuro to Participate in Multiple Global Healthcare Conferences in the Fourth Quarter of 2025
Via ACCESS Newswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
< Previous 1 2 3 4 5 Next >